Why the study?
What is the incidence of venous thromboembolism in asymptomatic carriers of antithrombin, protein C, or protein S deficiency without continuous anticoagulant prophylaxis?
What is the incidence of venous thromboembolism in asymptomatic carriers of antithrombin, protein C, or protein S deficiency without continuous anticoagulant prophylaxis?
Continuous anticoagulant prophylaxis is not warranted in asymptomatic individuals with antithrombin, protein C, or protein S deficiency, as the annual incidence of VTE is low (1.5%), though prophylaxis is necessary during high-risk periods.
Answers are grounded in this paper and cite their sources.
May not warrant continuous prophylaxis in asymptomatic carriers; leaves open need for risk-stratified trials in high-risk settings.
Deficiencies of antithrombin, protein C, and protein S are associated with an increased risk of venous thromboembolism. The objective of this study was to prospectively assess the incidence of venous thromboembolism in nontreated asymptomatic subjects with such a deficiency. We conducted a prospective cohort study in asymptomatic family members of unselected patients who presented with a venous thromboembolic event and who were found to have a deficiency of antithrombin, protein C, or protein S. No anticoagulant prophylaxis was given to the study participants, except during risk periods for venous thromboembolism. All venous thromboembolic events were diagnosed by objective diagnostic tests. A total of 208 individuals with a mean age of 37 years (range, 15 to 79) were included in the study. A total of 611 patient observation years was obtained. Nine venous thromboembolic events occurred, resulting in an annual incidence of 1.5% (95% confidence interval [CI], 0.7 to 2.8) for the 3 deficiencies combined. Five of these events occurred spontaneously, resulting in an annual incidence of spontaneous venous thromboembolism of 0.8% (95% CI, 0.3 to 1.9). For antithrombin, protein C, and protein S deficiencies separately, this figure was 1.6%, 1.0%, and 0.4%, respectively. Thirty-four subjects experienced a total of 40 risk periods during which 4 venous thromboembolic events occurred (10% per risk period). We conclude that the use of continuous anticoagulant prophylaxis seems not warranted in asymptomatic individuals with a deficiency of antithrombin, protein C, or protein S. During risk periods for venous thromboembolism, adequate anticoagulant prophylaxis is necessary.
No takes yet. Share an insight, caveat, or question.
Sanson et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: